CA2923160A1 - Immune system modulators - Google Patents

Immune system modulators Download PDF

Info

Publication number
CA2923160A1
CA2923160A1 CA2923160A CA2923160A CA2923160A1 CA 2923160 A1 CA2923160 A1 CA 2923160A1 CA 2923160 A CA2923160 A CA 2923160A CA 2923160 A CA2923160 A CA 2923160A CA 2923160 A1 CA2923160 A1 CA 2923160A1
Authority
CA
Canada
Prior art keywords
peptide
cancer
seq
amino acid
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2923160A
Other languages
English (en)
French (fr)
Inventor
Leif Hakansson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CANIMGUIDE THERAPEUTICS AB
Original Assignee
CANIMGUIDE THERAPEUTICS AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CANIMGUIDE THERAPEUTICS AB filed Critical CANIMGUIDE THERAPEUTICS AB
Publication of CA2923160A1 publication Critical patent/CA2923160A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2923160A 2013-09-09 2014-09-08 Immune system modulators Abandoned CA2923160A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361875598P 2013-09-09 2013-09-09
US61/875,598 2013-09-09
PCT/US2014/054612 WO2015035332A1 (en) 2013-09-09 2014-09-08 Immune system modulators

Publications (1)

Publication Number Publication Date
CA2923160A1 true CA2923160A1 (en) 2015-03-12

Family

ID=51585229

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2923160A Abandoned CA2923160A1 (en) 2013-09-09 2014-09-08 Immune system modulators

Country Status (10)

Country Link
US (3) US9657059B2 (https=)
EP (2) EP3043810B1 (https=)
JP (2) JP6886816B2 (https=)
KR (1) KR102162323B1 (https=)
CN (2) CN111732652A (https=)
AU (1) AU2014317884B2 (https=)
CA (1) CA2923160A1 (https=)
DK (1) DK3043810T3 (https=)
ES (1) ES2777939T3 (https=)
WO (1) WO2015035332A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2608803T3 (es) 2007-05-08 2017-04-17 Canimguide Therapeutics Ab Estructuras inmunorreguladoras procedentes de proteínas naturales
EP3043810B1 (en) 2013-09-09 2019-10-23 CanImGuide Therapeutics AB Immune system modulators
WO2016144650A1 (en) * 2015-03-06 2016-09-15 Canimguide Therapeutics Ab Immune system modulators and compositions
US9793852B2 (en) 2015-07-15 2017-10-17 Solarcity Corporation Clamp and bowl mounting system for photovoltaic modules
KR101896777B1 (ko) 2016-10-06 2018-09-07 현대자동차주식회사 내습성이 향상된 배리어 필름의 제조방법 및 이에 의해 제조된 배리어 필름
US20210401926A1 (en) * 2018-09-28 2021-12-30 Canimguide Therapeutics Ab Pharmaceutical formulations of peptide inhibitors
JP7734917B2 (ja) 2019-01-28 2025-09-08 ミトコンドリア エモーション， インク． トランス－４－ヒドロキシシクロヘキシルフェニルアミドマイトフュージン活性化物質及びその使用方法
AU2019427489B2 (en) 2019-01-28 2025-03-13 Mitochondria Emotion, Inc. Mitofusin activators and methods of use thereof
CN111649776A (zh) * 2020-04-14 2020-09-11 东莞市创宏医疗科技有限公司 一种无屏检测系统
US20240197761A1 (en) * 2021-04-16 2024-06-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. Fucosylation and immune modulation in cancer
GB202211043D0 (en) * 2022-07-28 2022-09-14 Univ Birmingham Peptide agonist
KR20250040766A (ko) * 2023-09-15 2025-03-25 (주)케어젠 발모 촉진 및 탈모 억제 활성을 갖는 펩타이드 및 이의 용도

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US715368A (en) 1902-05-29 1902-12-09 Isaac N Graham Cutter-bar for harvesters or mowers.
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993016177A1 (en) 1992-02-11 1993-08-19 Cell Genesys, Inc. Homogenotization of gene-targeting events
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
IT1263831B (it) 1993-01-29 1996-09-04 Paolo Chiesi Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
SE502408C2 (sv) 1993-09-30 1995-10-16 Dataliner Ab Skalmönster vid lägesbestämning med hjälp av en snäv mätstråle
US5888767A (en) 1996-11-27 1999-03-30 The Johns Hopkins University School Of Medicine Method of using a conditionally replicating viral vector to express a gene
EP1415982A1 (en) 1998-03-11 2004-05-06 G.D. SEARLE & CO. Halogenated amidino amino acid derivatives useful as nitric oxide synthase inhibitors
AUPP616498A0 (en) 1998-09-25 1998-10-15 University Of Queensland, The Synthesis of cyclic peptides
US7024312B1 (en) 1999-01-19 2006-04-04 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US6703491B1 (en) * 1999-03-17 2004-03-09 Exelixis, Inc. Drosophila sequences
US20040031072A1 (en) * 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
ATE340571T1 (de) 2000-01-18 2006-10-15 Univ Mcgill Pharmazeutische zubereitungen enthaltend beta- turn peptidomimetische zyklische substanzen
US6495674B1 (en) 2000-02-25 2002-12-17 The Salk Institute For Biological Studies Evectins and their use
US7252952B2 (en) 2000-03-06 2007-08-07 Rigel Pharmaceuticals, Inc. In vivo production of cyclic peptides for inhibiting protein—protein interaction
US6417237B1 (en) 2000-06-08 2002-07-09 The Board Of Trustees Of The University Of Illinois Macromolecular drug complexes and compositions containing the same
EP1385544B1 (en) * 2001-04-30 2008-09-24 Eli Lilly And Company Humanized antibodies
KR100566911B1 (ko) 2001-06-25 2006-04-03 주식회사 삼양사 약물 전달체용 음이온기-함유 양친성 블록 공중합체 및 그의 양이온성 약물과의 복합체
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
SI1461359T1 (sl) * 2002-01-18 2007-06-30 Pf Medicament Nova anti IGF-IR protitelesa in njihova uporaba
US7153685B2 (en) 2002-03-11 2006-12-26 The Board Of Trustees Of The University Of Illinois Tamoxifen and 4-hydroxytamoxifen-activated system for regulated production of proteins in eukaryotic cells
AU2003232872A1 (en) 2002-05-27 2003-12-12 Ostergotlands Lans Landsting Method for determining immune system affecting compounds
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
WO2004022097A1 (en) * 2002-09-05 2004-03-18 Medimmune, Inc. Methods of preventing or treating cell malignancies by administering cd2 antagonists
US20090183270A1 (en) * 2002-10-02 2009-07-16 Adams Thomas R Transgenic plants with enhanced agronomic traits
US20040208921A1 (en) 2003-01-14 2004-10-21 Ho Rodney J. Y. Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues
EP1613774A2 (en) 2003-03-10 2006-01-11 Applera Corporation Genetic polymorphisms associated with stenosis, methods of detection and uses thereof
CA2520846C (en) 2003-03-31 2013-09-24 Mcmaster University Aptamer selection method
AU2003902875A0 (en) * 2003-06-10 2003-06-26 The University Of Melbourne Immunomodulating compositions, uses therefor and processes for their production
KR20130065723A (ko) 2003-06-27 2013-06-19 암젠 프레몬트 인코포레이티드 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도
ES2383300T3 (es) 2003-11-13 2012-06-20 Hanmi Holdings Co., Ltd Fragmento Fc de IgG para un vehículo de fármacos y procedimiento para su preparación
NZ579482A (en) 2004-06-01 2011-02-25 Genentech Inc Antibody drug conjugates and methods
KR101131727B1 (ko) 2004-06-11 2012-03-28 가톨릭대학교 산학협력단 ＣＥＡ-특이적인 세포독성 Ｔ세포를 생성하는 재조합 아데노바이러스 ＡｄＶＣＥＡ로 트랜스덕션된 수지상세포, 이를 포함하는 백신 및 약제학적 조성물
FR2873699B1 (fr) 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
SE0402536D0 (sv) 2004-10-20 2004-10-20 Therim Diagnostica Ab Immunoregulation in cancer, chronic inflammatory and autoimmune diseases
EP1875246B1 (en) 2005-04-15 2016-10-05 CanImGuide Therapeutics AB Diagnostic method for detecting cancer by measuring amount of a cytokine like il-6
CN101400646A (zh) 2005-11-08 2009-04-01 Ambrx公司 用于修饰非天然氨基酸和非天然氨基酸多肽的促进剂
WO2007070659A2 (en) 2005-12-14 2007-06-21 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
US7812133B2 (en) 2005-12-16 2010-10-12 Genentech, Inc Anti-OX40L antibodies and methods using same
US7816324B2 (en) 2007-03-13 2010-10-19 Board Of Regents, The University Of Texas System Composition and method for the treatment of diseases affected by a peptide receptor
ES2608803T3 (es) * 2007-05-08 2017-04-17 Canimguide Therapeutics Ab Estructuras inmunorreguladoras procedentes de proteínas naturales
WO2009047360A1 (en) * 2007-10-11 2009-04-16 Novo Nordisk A/S Il-21 antibodies
RU2360924C1 (ru) * 2007-12-21 2009-07-10 Институт биохимии им. А.А. Баха РАН Маркер рака предстательной железы
EP4012714A1 (en) 2010-03-23 2022-06-15 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
US8455624B2 (en) * 2011-06-03 2013-06-04 University Of South Alabama Methods and compositions for detecting endometrial or ovarian cancer
EP3043810B1 (en) 2013-09-09 2019-10-23 CanImGuide Therapeutics AB Immune system modulators
WO2016144650A1 (en) 2015-03-06 2016-09-15 Canimguide Therapeutics Ab Immune system modulators and compositions

Also Published As

Publication number Publication date
EP3043810A1 (en) 2016-07-20
CN105744944B (zh) 2020-07-07
AU2014317884B2 (en) 2017-09-07
JP2016531583A (ja) 2016-10-13
US10301356B2 (en) 2019-05-28
ES2777939T3 (es) 2020-08-06
JP6886816B2 (ja) 2021-06-16
EP3043810B1 (en) 2019-10-23
JP2020019803A (ja) 2020-02-06
US20170298096A1 (en) 2017-10-19
CN105744944A (zh) 2016-07-06
CN111732652A (zh) 2020-10-02
EP3656391A1 (en) 2020-05-27
KR102162323B1 (ko) 2020-10-06
US20160311854A1 (en) 2016-10-27
US20190375789A1 (en) 2019-12-12
KR20160054531A (ko) 2016-05-16
US9657059B2 (en) 2017-05-23
DK3043810T3 (da) 2020-01-27
WO2015035332A1 (en) 2015-03-12

Similar Documents

Publication Publication Date Title
US10301356B2 (en) Immune system modulators
AU2014317884A1 (en) Immune system modulators
US9120874B2 (en) Methods of immunoregulation by albumin neo-structures
JP5652987B2 (ja) ヒトＩｇＧＦｃレセプターＩＩｂ（ＦｃγＲＩＩｂ）に結合する物質
US10881709B2 (en) Immune system modulators and compositions
AU2023228683B2 (en) Method of treating pancreatic cancer
EP2722342A1 (en) Methods and compositions for the treatment of pancreatic cancer
HK40031369A (en) Immune system modulators
HK1226670B (en) Immune system modulators
HK1226670A1 (en) Immune system modulators
HK1248574B (en) Immune system modulators and compositions
CN120769863A (zh) SARS-CoV-2刺突蛋白结合分子
WO2006026172A2 (en) Use of soluble cd26 as inhibitor of angiogenesis and inflammation
HK40028398A (en) Immunoregulatory structures from normally occurring proteins
KR20190042281A (ko) 돼지 조직인자 세포외 도메인 단백질을 특이적으로 인식하는 단일클론항체 및 이의 용도

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190905

FZDE Discontinued

Effective date: 20240307